CN102846931A - Application of Chinese medicine composition in preparation of hyperthyroidism treatment drug - Google Patents
Application of Chinese medicine composition in preparation of hyperthyroidism treatment drug Download PDFInfo
- Publication number
- CN102846931A CN102846931A CN2011101773357A CN201110177335A CN102846931A CN 102846931 A CN102846931 A CN 102846931A CN 2011101773357 A CN2011101773357 A CN 2011101773357A CN 201110177335 A CN201110177335 A CN 201110177335A CN 102846931 A CN102846931 A CN 102846931A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- medicine composition
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides application of Chinese medicine composition in preparation of hyperthyroidism treatment drug. The Chinese medicine composition is composed of Radix Ginseng, lilyturf root, skunk bush, Radix Salivae Miltiorrhizae, parched Semen Ziziphi Spinosae, loranthus, Radix Paeoniae Rubra, Eupolyphaga Seu Steleophaga and Radix Et Rhizoma Nardostachyos. Clinical experiments confirm the Chinese medicine composition has significant clinical therapeutic effect for hyperthyroidism.
Description
Technical field
The present invention relates to the application of a kind of Chinese medicine composition in the medicine of preparation treatment hyperthyroidism, belong to the Chinese herbal medicine application.
Background technology
Hyperthyroidism is the abbreviation of hyperthyroidism, is a kind of very common endocrinopathy.Refer to cause thyroid function to strengthen by a variety of causes, thyroid hormone secretion is too much, or thyroxin (T3, T4) level in blood a series of hypermetabolism diseases of increasing the multisystems such as organism nervous system, blood circulation and digestive system cardiovascular system that cause.That this disease clinical manifestation is mainly is nervous, To Be Protected from Heat, hyperhidrosis, tachycardia, bulimia, fatigue and weak, become thin, exophthalmos, hands tremor of the tongue are trembled, weight loss and emotion are emotional etc., badly influence daily life, bring very large psychology and physiological load to the patient.
The conventional treatments of general hyperthyroidism has routine medication, operative treatment, the iodine 131 radiotherapy, conventional antithyroid drug (ATD) mainly contain Thiourea (such as propylthiouracil, PTU) and imidazoles (such as thiamazole, MM).All there is comparatively serious side effect in these medicines, as: leukopenia, agranulocytosis, severe hepatic injury, exfoliative dermatitis etc.Iodine 131 is comparatively safe, administration time is long, also has many use taboos, as: after 1, the hyperthyroid patient of gestation and age of sucking, parent are taken in radioiodine, can enter by Placenta Hominis or milk fetus or baby's thyroid, cause fetus or baby's hypothyroidism (cretinism).2, the age is at the first trouble hyperthyroid patient below 20 years old.3, hyperthyroidism is in the recent period with the myocardial infarction person.Behind 131 iodine therapies, the release of thyroxin can increase the weight of the heart burden, therefore can not use radioiodine therapy.4, there are the nonfunction such as the severe heart, liver, kidney or active tuberculosis to examine.5, leukocyte is lower than 3 * 10
9/ liter or neutrophilic granulocyte be lower than 5 * 10
9/ rise the counter.6, severe infiltrative exophthalmos disease.7, the hyperthyroidism crisis phase.8, the person that in the past once can not take the photograph the iodine 131 with a large amount of iodine.
Patent ZL02146572.X discloses a kind of pharmaceutical composition for the treatment of Coronary heart disease ventricular early throb and preparation method thereof, and present patent application quotes in full the content that patent ZL02146572.X puts down in writing.The application of unexposed this pharmaceutical composition of this patent in preparation treatment hyperthyroidism medicine.
Summary of the invention
The purpose of this invention is to provide the application of a kind of Chinese medicine composition in the medicine of preparation treatment hyperthyroidism, this Chinese medicine composition is made by the crude drug of following weight portion:
Radix Ginseng 45-180 part, Radix Ophiopogonis 50-200 part, Fructus Corni 125-450 part, Radix Salviae Miltiorrhizae 125-450 part, Semen Ziziphi Spinosae (parched) 95-400 part, Herba Taxilli 95-400 part, Radix Paeoniae Rubra 45-200 part, Eupolyphaga Seu Steleophaga 35-150 part, Radix Et Rhizoma Nardostachyos 45-200 part, Rhizoma Coptidis 25-90 part, Fructus Schisandrae Sphenantherae 35-150 part, Os Draconis 75-300 part.
The weight ratio of Chinese medicine composition Raw medicine of the present invention is preferably:
89 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 224 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 75 parts of Eupolyphaga Seu Steleophagas, 89 parts of Radix Et Rhizoma Nardostachyos, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
The weight ratio of Chinese medicine composition Raw medicine of the present invention also is preferably:
45 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 225 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 45 parts of Radix Et Rhizoma Nardostachyos, 35 parts of Eupolyphaga Seu Steleophagas, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
The weight ratio of Chinese medicine composition Raw medicine of the present invention also is preferably:
90 parts of Radix Ginsengs, 135 parts of Radix Ophiopogonis, 270 parts of Fructus Corni, 200 parts of Radix Salviae Miltiorrhizaes, 150 parts of Semen Ziziphi Spinosae (parched)s, 150 parts of Herba Taxillis, 100 parts of Radix Paeoniae Rubra, 100 parts of Eupolyphaga Seu Steleophagas, 95 parts of Radix Et Rhizoma Nardostachyos, 60 parts of Rhizoma Coptidis, 75 parts of Fructus Schisandrae Sphenantheraes, 150 parts of Os Draconis.
In the application of the present invention, the active component of this Chinese medicine composition is made by the following step:
A) people participates in 70% alcohol reflux 3 times, and merge extractive liquid, filters, and is concentrated, and oven dry is ground into fine powder;
B) Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 70% alcohol reflux 3 times jointly, and merge extractive liquid, filters, and is condensed into extractum;
C) Eupolyph aga sinesis Walker is broken into fine powder;
D) Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis decoct with water 2 times, and merge extractive liquid, filters, and gets the water extracted immersing paste;
E) with step b) and d) gained extractum merge, concentrated, add step c) fine drug powder of gained, oven dry is ground into fine powder, adds a) gained fine drug powder of step, mixing namely gets this Chinese medicine composition active component.
In the application of the present invention, described Chinese medicinal composition preparation dosage form is capsule, tablet, granule, a kind of in powder or the oral liquid formulations, for above-mentioned dosage form can be realized, need when these dosage forms of preparation, to add the acceptable adjuvant of pharmacy, for example: filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic etc., filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc., disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc., lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc., suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc., binding agent comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc., sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc., correctives comprises: sweeting agent and various essence, and antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, the acetic acid chloroethene is fixed, the Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods.
Preferably, the preparation method of capsule of the present invention is:
A) people participates in 8 times of amount 70% alcohol reflux 3 times, and 3 hours for the first time, each 2 hours later on, merge extractive liquid, filtered, and Recycled ethanol is concentrated, and oven dry is ground into 80 order powder;
B) Fructus Schisandrae Chinensis, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 8 times of amount 70% alcohol reflux 3 times, and merge extractive liquid, filters, and concentration and recovery ethanol gets alcohol-extracted extract;
C) Eupolyphaga seu Steleophaga is ground into 80 order powder;
D) Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis add 9 times of amount decoctions of water 2 times, and merge extractive liquid, filters, and gets the water extracted immersing paste;
E) with step b) and d) gained extractum merge, concentrated, add step c) fine drug powder of gained, oven dry is ground into 80 order powder, adds a) gained fine drug powder of step, mixing is encapsulated and get final product.
The inventor thinks that hyperthyroidism belongs to due to deficiency of both QI and YIN cause the network void of heart network not flourish (networks of meridians) and the channels stasis blocking (network of venation).Channels is the Rong Ze lack of preservation of spirit not, and the channels stasis blocking is with the passing of time heat-transformation then, disturbs the mind in the asthenic fire and causes irritability, and Chinese medicine composition of the present invention is the compound Chinese medicinal preparation according to the research and development of traditional Chinese medical science network ens morbi.Chief component Radix Ginseng, Radix Ophiopogonis, Radix Salviae Miltiorrhizae, Radix Et Rhizoma Nardostachyos, Fructus Schisandrae Chinensis have supplementing QI and nourishing YIN, promoting blood circulation to remove obstruction in the collateral, the effect of clearing away heart-fire for tranquillization.But multipath, too many levels, hypermetabolism due to many target treatments hyperthyroidism, clinical observation shows, traditional Chinese medicine composition for treating hyperthyroidism of the present invention, determined curative effect, can significantly reduce the blood thyroid hormones level, without drug dependence and toleration, also have no adverse reaction, easily accepted by the patient.
The consumption of Chinese medicine composition of the present invention by active component crude drug gross weight, is 7-28 gram/day, but takes every day once, preferably divides and takes for 2-4 time.
For illustrating the activity of traditional Chinese medicine composition for treating hyperthyroidism of the present invention, use the capsule (hereinafter referred to as medicine of the present invention) that makes by above-described embodiment 1 method to carry out following clinical trial.
1 data and method
1.1 physical data is from June, 2008 to 2010 year December, Hebei Medical University is attached accepts hyperthyroid patient 71 examples for medical treatment altogether with mountain range hospital, all makes a definite diagnosis in conjunction with clinical manifestation and serum blood examination survey and thyroid iodine uptake mensuration etc.Man's 32 examples, women 39 examples.Minimum 17 years old of age, maximum 74 years old, average 51.6 years old.The course of disease is the shortest 4 months, and is the longest 7 years, average 2.8 years.All cases are all carried out the stadium typing with reference to " practical endocrinology ": light-duty 38 examples, medium-sized 26 examples, heavy 7 examples.The patient is according to the age, sex, and the course of disease, stadium, clinical manifestations etc. are divided into experimental group and matched group at random.Experimental group 36 examples wherein, matched group 35 examples, two groups of there was no significant differences aspect physical data have comparability.
1.2 two groups of patients of method all carry out the whole body assessment in conjunction with clinical manifestation and diagnostic result, formulate the therapeutic regimen that is fit to the patient.Treatment of control group: use antithyroid drug (ATD) propylthiouracil or thiamazole.Propylthiouracil is just controlled phase 200～300mg/ days, and thiamazole is just controlled phase 20～30mg/ days, and 6 months is a course for the treatment of, according to clinical feedback adjusting dosage.The experimental group treatment: use medicine of the present invention, dosage is generally 2-4 tablets/time, and 3 times/days, 6 months is a course for the treatment of.(T3 during the experiment beginning
0, T4
0), test mid-term (3 months, T3
In,T4
In), experiment finishes (T3
The end, T4
The end) time respectively measure the blood thyroid hormones level one time, carry out statistical analysis.
1.3 effect assessment recovery from illness: clinical symptom disappearance after the treatment, body weight increases, and it is normal that the thyroid function indices progressively recovers.Effectively: clinical symptoms after the treatment, thyroid function indices and body weight have improvement in various degree.Invalid: clinical symptoms after the treatment, thyroid function indices etc. are unchanged or increase the weight of.Wherein to add effective percentage be total effective rate to cure rate.
2 results
2.1 blood thyroid hormones level
Through treatment, two groups of hyperthyroid patient blood thyroid hormones level all have reduction in various degree, and experimental group blood thyroid hormones level all significantly is lower than matched group when experiment mid-term and experiment finish, and see for details and see Table 1, table 2.
Table 1 liang group blood samples of patients thyroxin (T3) level relatively
| Group | Example number N | T3 0(ng/ml) | T3 In(ng/ml) | T3 The end(ng/ml) |
| Experimental group | 36 | 4.30±1.95 | 2.53±1.37* | 1.47±0.87* |
| Matched group | 35 | 4.27±1.78 | 3.28±1.21 | 2.35±1.14 |
Annotate: compare * P＜0.05 with matched group.
Table 2 liang group blood samples of patients thyroxin (T4) level relatively
| Group | Example number N | T4 0(ng/ml) | T4 In(ng/ml) | T4 The end(ng/ml) |
| Experimental group | 36 | 224.51±57.18 | 147.95±19.38* | 121.11±15.39* |
| Matched group | 35 | 219.21±59.43 | 179.24±23.47 | 150.78±21.18 |
Annotate: compare * P＜0.05 with matched group.
2.2 curative effect
Through treatment, two groups of hyperthyroid patients all have recovery in various degree, have no obvious side reaction during the treatment.Wherein experimental group patient's total effective rate is 97.2%(35/36), obvious effective rate is 86.1%(31/36), matched group patient total effective rate is 80.0%(28/35), obvious effective rate is 62.9%(22/35), experimental group aspect total effective rate and the obvious effective rate aspect all significantly be better than matched group (P＜0.05), curative effect statistics sees Table shown in 3.
Table 3 liang group curative effect relatively
| Group | The example number | Produce effects | Effectively | Invalid | Obvious effective rate | Total effective rate |
| Experimental group | 36 | 31 | 4 | 1 | 86.1%* | 97.2%* |
| Matched group | 35 | 22 | 6 | 7 | 62.9% | 80.0% |
Annotate: compare * P＜0.05 between group.
3 conclusions
Medicine of the present invention can effectively be treated hyperthyroidism, and clinical total effective rate is significantly higher than conventional Treatment of Hyperthyroidism medicine, and can effectively reduce the blood thyroid hormones level, the clinical treatment that can be used for hyperthyroidism.
The specific embodiment
Following embodiment is used for illustrating the preparation of Chinese medicine composition of the present invention, but it can not consist of any restriction to scope of the present invention.
Embodiment 1
For the ease of the application of this traditional Chinese medicine composition for treating hyperthyroidism, this Chinese medicine composition is prepared as capsule
Prescription:
Radix Ginseng 89g 112g Radix Ophiopogonis Fructus Corni 224g Radix Salviae Miltiorrhizae 224g
Semen Ziziphi Spinosae (parched) 186g Herba Taxilli 186g Radix Paeoniae Rubra 89g Eupolyphaga Seu Steleophaga 75g
Radix Et Rhizoma Nardostachyos 89g Rhizoma Coptidis 45g Fructus Schisandrae Sphenantherae 67g Os Draconis 149g
Preparation method:
A) in the above-mentioned prescription, Radix Ginseng 8 usefulness are doubly measured 70% alcohol reflux 3 times, and 3 hours for the first time, each 2 hours later on, merge extractive liquid, filtered, and Recycled ethanol is concentrated, and oven dry is ground into 80 order fine powders, and is for subsequent use;
B) in the above-mentioned prescription, Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos are measured 70% alcohol reflux 3 times with 8 times, and merge extractive liquid, filters, Recycled ethanol, and the concentrated extractum that to get, for subsequent use;
C) in the above-mentioned prescription, Eupolyph aga sinesis Walker is broken into 80 order fine powders, and is for subsequent use;
D) in the above-mentioned prescription, Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis add 9 times of water gagings and decoct 2 times, and merge extractive liquid, filters, and concentrates to get the water extracted immersing paste, and is for subsequent use;
E) with step b) and d) gained extractum merge, concentrated, add step c) the fine drug powder oven dry of gained, be ground into 80 order fine powders, add a) gained fine drug powder of step, mixing, 1000 capsules of packing into.
Usage and consumption: oral.One time 2～4,3 times on the one.
Embodiment 2
For the ease of the application of this traditional Chinese medicine composition for treating hyperthyroidism, this Chinese medicine composition is prepared as tablet
Prescription:
Radix Ginseng 45g 112g Radix Ophiopogonis Fructus Corni 224g Radix Salviae Miltiorrhizae 225g Semen Ziziphi Spinosae (parched) 186g
Herba Taxilli 186g Radix Paeoniae Rubra 89g Radix Et Rhizoma Nardostachyos 45g Eupolyphaga Seu Steleophaga 35g Rhizoma Coptidis 45g
Fructus Schisandrae Sphenantherae 67g Os Draconis 149g.
Preparation method:
A) in the above-mentioned prescription, Radix Ginseng 10 usefulness are doubly measured 70% alcohol reflux 3 times, and 3 hours for the first time, each 2 hours later on, merge extractive liquid, filtered, and Recycled ethanol is concentrated, and oven dry is ground into 80 order fine powders, and is for subsequent use;
B) in the above-mentioned prescription, Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos are measured 70% alcohol reflux 3 times with 12 times, and merge extractive liquid, filters, Recycled ethanol, and the concentrated extractum that to get, for subsequent use;
C) in the above-mentioned prescription, Eupolyph aga sinesis Walker is broken into 100 order fine powders, and is for subsequent use;
D) in the above-mentioned prescription, Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis add 8 times of water gagings and decoct 2 times, and merge extractive liquid, filters, and concentrates to get the water extracted immersing paste, and is for subsequent use;
E) with step b) and d) gained extractum merge, concentrated, add step c) the fine drug powder oven dry of gained, be ground into 60 order fine powders, add a) gained fine drug powder of step, mixing, preparation process is pressed into 1000 routinely.
Usage and consumption: oral.One time 2～4,3 times on the one.
Embodiment 3
For the ease of the application of this traditional Chinese medicine composition for treating hyperthyroidism, this Chinese medicine composition is prepared as granule
Prescription:
Radix Ginseng 175g 192g Radix Ophiopogonis Fructus Corni 421g Radix Salviae Miltiorrhizae 440g Semen Ziziphi Spinosae (parched) 395g
Herba Taxilli 396g Radix Paeoniae Rubra 188g Eupolyphaga Seu Steleophaga 98g Radix Et Rhizoma Nardostachyos 188g Rhizoma Coptidis 85g
Fructus Schisandrae Sphenantherae 147g Os Draconis 278g.
Preparation method:
A) in the above-mentioned prescription, Radix Ginseng 12 usefulness are doubly measured 70% alcohol reflux 3 times, and 3 hours for the first time, each 2 hours later on, merge extractive liquid, filtered, and Recycled ethanol is concentrated, and oven dry is ground into 100 order fine powders, and is for subsequent use;
B) in the above-mentioned prescription, Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos are measured 70% alcohol reflux 3 times with 9 times, and merge extractive liquid, filters, Recycled ethanol, and the concentrated extractum that to get, for subsequent use;
C) in the above-mentioned prescription, Eupolyph aga sinesis Walker is broken into 80 order fine powders, and is for subsequent use;
D) in the above-mentioned prescription, Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis add 6 times of water gagings and decoct 2 times, and merge extractive liquid, filters, and concentrates to get the water extracted immersing paste, and is for subsequent use;
E) with step b) and d) gained extractum merge, concentrated, add step c) the fine drug powder oven dry of gained, be ground into 100 order fine powders, add a) gained fine drug powder of step, mixing is made 1000 bags of granules according to conventional formulation.
Usage and consumption: oral.One time 2～4 bags, 3 times on the one.
Claims (8)
1. the application of Chinese medicine composition in the medicine of preparation treatment hyperthyroidism is characterized in that, this Chinese medicine composition is made by the crude drug of following weight portion:
Radix Ginseng 45-180 part, Radix Ophiopogonis 50-200 part, Fructus Corni 125-450 part, Radix Salviae Miltiorrhizae 125-450 part, Semen Ziziphi Spinosae (parched) 95-400 part, Herba Taxilli 95-400 part, Radix Paeoniae Rubra 45-200 part, Eupolyphaga Seu Steleophaga 35-150 part, Radix Et Rhizoma Nardostachyos 45-200 part, Rhizoma Coptidis 25-90 part, Fructus Schisandrae Sphenantherae 35-150 part, Os Draconis 75-300 part.
2. application as claimed in claim 1 is characterized in that, this Chinese medicine composition is made by the crude drug of following weight portion:
89 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 224 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 75 parts of Eupolyphaga Seu Steleophagas, 89 parts of Radix Et Rhizoma Nardostachyos, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
3. application as claimed in claim 1 is characterized in that, this Chinese medicine composition is made by the crude drug of following weight portion:
45 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 225 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 45 parts of Radix Et Rhizoma Nardostachyos, 35 parts of Eupolyphaga Seu Steleophagas, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
4. application as claimed in claim 1 is characterized in that, this Chinese medicine composition is made by the crude drug of following weight portion:
90 parts of Radix Ginsengs, 135 parts of Radix Ophiopogonis, 270 parts of Fructus Corni, 200 parts of Radix Salviae Miltiorrhizaes, 150 parts of Semen Ziziphi Spinosae (parched)s, 150 parts of Herba Taxillis, 100 parts of Radix Paeoniae Rubra, 100 parts of Eupolyphaga Seu Steleophagas, 95 parts of Radix Et Rhizoma Nardostachyos, 60 parts of Rhizoma Coptidis, 75 parts of Fructus Schisandrae Sphenantheraes, 150 parts of Os Draconis.
5. such as each described application of claim 1-4, it is characterized in that, the active component of this Chinese medicine composition is made by the following step:
A) people participates in 70% alcohol reflux 3 times, and merge extractive liquid, filters, and is concentrated, and oven dry is ground into fine powder;
B) Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 70% alcohol reflux 3 times jointly, and merge extractive liquid, filters, and is condensed into extractum;
C) Eupolyph aga sinesis Walker is broken into fine powder;
D) Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis decoct with water 2 times, and merge extractive liquid, filters, and gets the water extracted immersing paste;
E) with step b) and d) gained extractum merge, concentrated, add step c) fine drug powder of gained, oven dry is ground into fine powder, adds a) gained fine drug powder of step, mixing namely gets this Chinese medicine composition active component.
6. such as each described application among the claim 1-4, it is characterized in that, the preparation formulation of described Chinese medicine composition is a kind of in capsule, tablet, granule, powder or the oral liquid formulations.
7. application as claimed in claim 6 is characterized in that this Chinese medicinal composition capsules agent made by following steps:
A) people participates in 8 times of amount 70% alcohol reflux 3 times, and 3 hours for the first time, each 2 hours later on, merge extractive liquid, filtered, and Recycled ethanol is concentrated, and oven dry is ground into 80 order powder;
B) Fructus Schisandrae Chinensis, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 8 times of amount 70% alcohol reflux 3 times, and merge extractive liquid, filters, and concentration and recovery ethanol gets alcohol-extracted extract;
C) Eupolyphaga seu Steleophaga is ground into 80 order powder;
D) Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis add 9 times of amount decoctions of water 2 times, and merge extractive liquid, filters, and gets the water extracted immersing paste;
E) with step b) and d) gained extractum merge, concentrated, add step c) fine drug powder of gained, oven dry is ground into 80 order powder, adds a) gained fine drug powder of step, mixing is encapsulated and get final product.
8. such as each described application of claim 1-4, it is characterized in that the application of described Chinese medicine composition in the medicine that reduces the blood thyroid hormones level.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101773357A CN102846931A (en) | 2011-06-29 | 2011-06-29 | Application of Chinese medicine composition in preparation of hyperthyroidism treatment drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101773357A CN102846931A (en) | 2011-06-29 | 2011-06-29 | Application of Chinese medicine composition in preparation of hyperthyroidism treatment drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102846931A true CN102846931A (en) | 2013-01-02 |
Family
ID=47394176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101773357A Pending CN102846931A (en) | 2011-06-29 | 2011-06-29 | Application of Chinese medicine composition in preparation of hyperthyroidism treatment drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102846931A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104173886A (en) * | 2014-09-02 | 2014-12-03 | 李晨芳 | Granules for treating senile hyperthyroidism and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101653547A (en) * | 2008-08-22 | 2010-02-24 | 河北以岭医药研究院有限公司 | Application of Chinese medicinal composition in preparation of medicament for preventing arrhythmia |
| CN101919984A (en) * | 2009-06-10 | 2010-12-22 | 南方医科大学南方医院 | Drug for treating hyperthyroidism and preparation method and application thereof |
| CN102302720A (en) * | 2011-09-06 | 2012-01-04 | 陈燕 | Chinese medicinal composition for treating hyperthyroidism |
| CN102451411A (en) * | 2010-10-27 | 2012-05-16 | 魏巍 | Preparation method of traditional Chinese medicine prescription for treating hyperthyroidism |
-
2011
- 2011-06-29 CN CN2011101773357A patent/CN102846931A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101653547A (en) * | 2008-08-22 | 2010-02-24 | 河北以岭医药研究院有限公司 | Application of Chinese medicinal composition in preparation of medicament for preventing arrhythmia |
| CN101919984A (en) * | 2009-06-10 | 2010-12-22 | 南方医科大学南方医院 | Drug for treating hyperthyroidism and preparation method and application thereof |
| CN102451411A (en) * | 2010-10-27 | 2012-05-16 | 魏巍 | Preparation method of traditional Chinese medicine prescription for treating hyperthyroidism |
| CN102302720A (en) * | 2011-09-06 | 2012-01-04 | 陈燕 | Chinese medicinal composition for treating hyperthyroidism |
Non-Patent Citations (4)
| Title |
|---|
| 吴以岭: "《络病学基础与临床研究》", 31 October 2007, 中国科学技术出版社 * |
| 国家药典委员会: "《国家药品标准 新药转正标准 第72册》", 31 March 2008 * |
| 王文雄: "参松养心胶囊治疗甲亢性心律失常疗效观察", 《现代中西医结合杂志》 * |
| 臧莉等: "采用中西医结合对40例甲亢患者的疗效分析", 《医学信息》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104173886A (en) * | 2014-09-02 | 2014-12-03 | 李晨芳 | Granules for treating senile hyperthyroidism and preparation method thereof |
| CN104173886B (en) * | 2014-09-02 | 2018-02-23 | 李晨芳 | A kind of granule for treating Hyperthyroidism In Elder Patients and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102210844B (en) | Chinese medicinal composition for treating chronic hepatitis and preparation method thereof | |
| CN101584796B (en) | Application of traditional Chinese medicine composition in preparing medicament for treating melancholia | |
| CN108403882A (en) | A kind of red sage root composition and preparation method thereof for treating coronary heart disease | |
| CN101653550B (en) | Chinese medicinal composition in preparation of medicament for treating type II diabetes | |
| CN101167838B (en) | Traditional Chinese medicinal preparation for treating coronary heart disease and angina pectoris and its preparing process | |
| CN102846931A (en) | Application of Chinese medicine composition in preparation of hyperthyroidism treatment drug | |
| CN101632783B (en) | Application of Chinese medicinal composition in preparing medicament for treating cor pulmonale | |
| CN101590173B (en) | Application of traditional Chinese medicine composition in preparing medicine for treating hypertensive intracerebral hemorrhage | |
| CN101559161B (en) | Application of traditional Chinese medicine composition in preparing medicament for curing tristimania | |
| CN102210807B (en) | Application of traditional Chinese medicine composition in preparation of medicaments for treating angina pectoris | |
| CN1943662B (en) | Preparation method of the Chinese traditional medicinal composition granules for treating galactophore disease and its products | |
| CN101313990B (en) | Application of a Chinese medicinal composition in preparing medicament for treating neurosis | |
| CN103623207A (en) | Applications of traditional Chinese medicine composition in preparation of medicines used for treating chronic heart failure together with arrhythmia | |
| CN101411814B (en) | Use of Chinese medicinal composition in preparing medicament for treating intraventricular block | |
| CN101653548B (en) | Chinese medicinal composition in preparation of medicament for treating hypotension | |
| CN103816466A (en) | Traditional Chinese medicine composition for treating chest stuffiness and pains as well as preparation and preparation method thereof | |
| CN116808162B (en) | Traditional Chinese medicine composition for preventing and treating ventricular premature contraction due to stagnation of gallbladder and phlegm and application thereof | |
| CN101744905B (en) | Applications of Chinese medicinal composition in preparation of medicament for treating pulmonary heart disease | |
| CN101683458B (en) | Application of a traditional Chinese medicine composition in preparation of medicament for treating vertigo | |
| CN106361889B (en) | Nourishing heart tune kidney particle and its preparation method and application | |
| CN101632729A (en) | Application of Chinese medicinal composition in preparing medicament for treating involution syndrome | |
| CN106943506B (en) | A pharmaceutical composition for treating climacteric syndrome, and its preparation method | |
| CN101564438B (en) | Application of Chinese medicinal composition in preparation of medicament for treating acute severe brain injury | |
| CN101411813B (en) | Use of Chinese medicinal composition in preparing medicament for treating chronic systolic heart failure | |
| CN101698051B (en) | Application of traditional Chinese medicine composite in preparing medicine treating climacteric syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130102 |